Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target

European Journal of Cell Biology

Volumn 91, Issue 2, 2012, Pages 139-149

  Crescioli, Clara ^a   Sottili, Mariangela ^b   Bonini, Paolo ^b   Cosmi, Lorenzo ^b   Chiarugi, Paola ^b   Romagnani, Paola ^b   Vannelli, Gabriella B ^b   Colletti, Marta ^a   Isidori, Andrea M ^c   Serio, Mario ^b   Lenzi, Andrea ^c   Di Luigi, Luigi ^a  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autoimmunity; Biomolecular target(s); CXCL10; Human skeletal muscle cells; Immunosuppressants; Inflammation; Inflammatory myopathies; Th1 polarization

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; MALE; MUSCLE CELL; PRIORITY JOURNAL; SKELETAL MUSCLE;

ANTIBODIES, MONOCLONAL; CELLS, CULTURED; CHEMOKINE CXCL10; CYCLOSPORINE; FETUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; METHYLPREDNISOLONE; MUSCLE CELLS; MUSCLE, SKELETAL; MYOSITIS; NF-KAPPA B; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855548726     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2011.09.011     Document Type: Article

References (57)

1. Andrès V., Walsh K. Myogenin expression, cell cycle withdrawal, and phenotypic differentiation are temporally separable events that precede cell fusion upon myogenesis. J. Cell Biol. 1996, 132:657-666.
2. Antonelli A., Fallahi P., Rotondi M., Ferrari S.M., Romagnani P., Grosso M., Ferrannini E., Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur. J. Endocrinol. 2006, 154:651-658.
3. Antonelli A., Rotondi M., Ferrari S.M., Fallahi P., Romagnani P., Franceschini S.S., Serio M., Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J. Clin. Endocrinol. Metab. 2006, 91:614-620.
4. Brzóska E., Przewoźniak M., Grabowska I., Jańczyk-Ilach K., Moraczewski J. Pax3 and Pax7 expression during myoblast differentiation in vitro and fast and slow muscle regeneration in vivo. Cell Biol. Int. 2009, 33:483-492.
5. Campbell J.D., Gangur V., Simons F.E., HayGlass K.T. Allergic humans are hypo-responsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop. FASEB J. 2004, 18:329-331.
6. Cao Y., Kumar R., Penn B., Berkes C.A., Kooperberg C., Boyer L.A., Young R.A., Tapscott S.J. Global and gene-specific analyses show distinct roles for Myod and Myog at a common set of promoters. EMBO J. 2006, 25:502-511.
7. Cosmi L., Annunziato F., Galli G., Maggi E., Nagata K., Romagnani S. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur. J. Immunol. 2000, 30:2972-2979.
8. Crescioli C., Cosmi L., Borgogni E., Santarlasci V., Gelmini S., Sottili M., Sarchielli E., Mazzinghi B., Francalanci M., Pezzatini A., Perigli G., Vannelli G.B., Annunziato F., Serio M. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J. Endocrinol. 2007, 195:145-155.
9. Crescioli C., Squecco R., Cosmi L., Sottili M., Gelmini S., Borgogni E., Sarchielli E., Scolletta S., Francini F., Annunziato F., Vannelli G.B., Serio M. Immunosuppression in cardiac graft rejection: a human in vitro model to study the potential use of new immunomodulatory drugs. Exp. Cell Res. 2008, 314:1337-1350.
10. Dalakas M.C. Polymyositis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 1991, 325:1487-1498.
11. Dalakas M.C. The molecular and cellular pathology of inflammatory muscle diseases. Curr. Opin. Pharmacol. 2001, 1:300-306.
12. Dalakas M.C. Pathophysiology of inflammatory and autoimmune myopathies. Presse Med. 2011, 40:e237-e247.
13. De Paepe B., De Keyzer K., Martin J.J., De Bleecker J.L. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies. Acta Neuropathol. 2005, 109:576-582.
14. De Paepe B., Creus K.K., De Bleecker J.L. Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann. N. Y. Acad. Sci. 2007, 1109:441-453.
15. De Paepe B., Creus K.K., De Bleecker J.L. Chemokines in idiopathic inflammatory myopathies. Front. Biosci. 2008, 13:2548-2577.
16. De Paepe B., Creus K.K., De Bleecker J.L. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 2009, 21:610-616.
17. De Rossi M., Bernasconi P., Baggi F., de Waal Malefyt R., Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int. Immunol. 2000, 12:1329-1335.
18. Dekel B., Reisner Y. Embryonic committed stem cells as a solution to kidney donor shortage. Expert Opin. Biol. Ther. 2004, 4:443-454.
19. Dieli-Conwright C.M., Spektor T.M., Rice J.C., Schroeder E.T. Hormone therapy attenuates exercise-induced skeletal muscle damage in postmenopausal women. J. Appl. Physiol. 2009, 107:853-858.
20. Fall N., Bove K.E., Stringer K., Lovell D.J., Brunner H.I., Weiss J., Higgins G.C., Bowyer S.L., Graham T.B., Thornton S., Grom A.A. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. Arthritis Rheum. 2005, 52:3175-3180.
21. Feferman T., Maiti P.K., Berrih-Aknin S., Bismuth J., Bidault J., Fuchs S., Souroujon M.C. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J. Immunol. 2005, 174:5324-5331.
22. Fibbi B., Filippi S., Morelli A., Vignozzi L., Silvestrini E., Chavalmane A., De Vita G., Marini M., Gacci M., Manieri C., Vannelli G.B., Maggi M. Estrogens regulate humans and rabbit epididymal contractility through the RhoA/Rho-kinase pathway. J. Sex. Med. 2009, 6:2173-2186.
23. Figarella-Branger D., Civatte M., Bartoli C., Pellissier J.F. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003, 28:659-682.
24. Foglia R.P., DiPreta J., Statter M.B., Donahoe P.K. Fetal allograft survival in immunocompetent recipients is age dependent and organ specific. Ann. Surg. 1986, 204:402-410.
25. Frasca L., Nasso M., Spensieri F., Fedele G., Palazzo R., Malavasi F., Ausiello C.M. IFN-gamma arms human dendritic cells to perform multiple effector functions. J. Immunol. 2008, 180:1471-1481.
26. Grundtman C., Malmstrom V., Lundberg I.E. Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res. Ther. 2007, 9:208-220.
27. Hancock W.W., Gao W., Csizmadia V., Faia K.L., Shemmeri N., Luster A.D. Donor-derived IP-10 initiates development of acute allograft rejection. J. Exp. Med. 2001, 193:975-980.
28. Hehlgans T., Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005, 115:1-20.
29. Lande R., Giacomini E., Serafini B., Rosicarelli B., Sebastiani G.D., Minisola G., Tarantino U., Riccieri V., Valesini G., Coccia E.M. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J. Immunol. 2004, 173:2815-2824.
30. Lazzeri E., Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2005, 5:109-118.
31. Lee E.Y., Lee Z.H., Song Y.W. CXCL10 and autoimmune diseases. Autoimmun. Rev. 2009, 8:379-383.
32. Lindberg C., Oldfors A., Tarkowski A. Local T-cell proliferation and differentiation in inflammatory myopathies. Scand. J. Immunol. 1995, 41:421-426.
33. Loell I., Lundberg I.E. Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies?. J. Intern. Med. 2011, 269:243-257.
34. Lundberg I., Brengman J.M., Engel A.G. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J. Neuroimmunol. 1995, 63:9-16.
35. Mantegazza R., Bernasconi P., Confalonieri P., Cornelio F. Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. J. Neurol. 1997, 244:277-287.
36. Nagaraju K., Raben N., Merritt G., Loeffler L., Kirk K. A variety of cytokines and immunologically relevant surface are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin. Exp. Immunol. 1998, 113:407-414.
37. Nielsen S., Pedersen B.K. Skeletal muscle as an immunogenic organ. Curr. Opin. Pharmacol. 2008, 8:346-351.
38. Nyberg P., Wikman A.L., Nennesmo I., Lundberg I. Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J. Rheumatol. 2000, 27:940-948.
39. Raju R., Vasconcelos O., Granger R., Dalakas M.C. Expression of IFN-gamma-inducible chemokines in inclusion body myositis. J. Neuroimmunol. 2003, 141:125-131.
40. Romagnani P., Lasagni L., Annunziato F., Serio M., Romagnani S. CXC chemokines the regulatory link between inflammation and angiogenesis. Trends Immunol. 2004, 25:201-209.
41. Romagnani P., Rotondi M., Lazzeri E., Lasagni L., Francalanci M., Buonamano A., Milani S., Vitti P., Chiovato L., Tonacchera M., Bellastella A., Serio M. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of subjects with recent onset Graves'disease. Am. J. Physiol. 2002, 161:195-206.
42. Rotondi M., Falorni A., De Bellis A., Laureti S., Ferruzzi P., Romagnani P., Buonamano A., Lazzeri E., Crescioli C., Mannelli M., Santeusanio F., Bellastella A., Serio M. Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J. Clin. Endocrinol. Metab. 2005, 90:2357-2363.
43. Rotondi M., Chiovato L., Romagnani S., Serio M., Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr. Rev. 2007, 28:492-520.
44. Sagrinati C., Sottili M., Mazzinghi B., Borgogni E., Adorini L., Serio M., Romagnani P., Crescioli C. Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells. Transpl. Int. 2010, 23:914-923.
45. Salomon I., Netzer N., Wildbaum G., Schif-Zuck S., Maor G., Karin N. Targeting the function of IFN-γ-inducible protein 10 suppresses ongoing adjuvant arthritis. J. Immunol. 2002, 169:2685-2693.
46. Schmidt J., Barthel K., Wrede A., Salajegheh M., Bähr M., Dalakas M.C. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008, 131:1228-1240.
47. Schwab N., Waschbisch A., Wrobel B., Lochmüller H., Sommer C., Wiendl H. Human myoblasts modulate the function of antigen-presenting cells. J. Neuroimmunol. 2008, 200:62-70.
48. Suvannavejh G.C., Lee H.O., Padilla J., Dal Canto M.C., Barrett T.A., Miller S.D. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell. Immunol. 2000, 205:24-33.
49. Szodoray P., Alex P., Knowlton N., Centola M., Dozmorov I., Csipo I., Nagy A.T., Constantin T., Ponyi A., Nakken B., Danko K. Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford, U.K.) 2010, 49:1867-1877.
50. Tournadre A., Miossec P. Chemokines and dendritic cells in inflammatory myopathies, Ann. Rheum. Dis. 2009, 68:300-304.
51. Tournadre A., Dubost J.J., Soubrier M. Treatment of inflammatory muscle disease in adults. Joint Bone Spine 2010, 77:390-394.
52. Wang X., Yue T.L., Ohlstein E.H., Sung C.P., Feuerstein G.Z. Interferonγ-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J. Biol. Chem. 1996, 271:24286-24293.
53. Wiendl H., Hohlfeld R., Kieseier B.C. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol. 2005, 26:373-380.
54. Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics 2008, 5:548-557.
55. Wolf R.E., Baethge B.A. Interleukin-1 alpha, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum. 1990, 33:1007-1014.
56. Yablonka-Reuveni Z., Day K., Vine A., Shefer G. Defining the transcriptional signature of skeletal muscle stem cells. J. Anim. Sci. 2008, 86:E207-E216.
57. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.